<DOC>
	<DOCNO>NCT01124656</DOCNO>
	<brief_summary>The purpose study determine safety tolerability pioglitazone-azilsartan , daily ( QD ) , patient type 2 diabetes mellitus .</brief_summary>
	<brief_title>Safety Tolerability Pioglitazone-Azilsartan Subjects With Type 2 Diabetes</brief_title>
	<detailed_description>AD-4833-536 combination AD-4833 ( pioglitazone ) TAK-536 ( azilsartan ) . Pioglitazone oral antidiabetic agent act reduce insulin resistance approve treatment adult patient type 2 diabetes mellitus . Azilsartan angiotensin II receptor blocker modulate renin-angiotensin-aldosterone system regulate blood pressure . In recent clinical trial conduct subject moderately poor poor control type 2 diabetes mellitus , azilsartan coadministered pioglitazone show reduction hemoglobin A1C fast plasma glucose level . After one week screening period , subject stratify receive start dose pioglitazone-azilsartan ( 30 mg + 20 mg 45 mg + 20 mg ) . The planned open-label treatment period 52 week ; however due formulation issue , study prematurely discontinue efficacy data analyze .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<criteria>Has type 2 diabetes glycosylated hemoglobin ≥7.0 % ≤ 11.0 % Screening . Has stable diabetic diet/exercise program . If receive antiglycemic therapy , he/she must ≤ two ( 2 ) antiglycemic agent stable regimen minimum 8 week prior Screening . Has clinical laboratory evaluation Screening ( include clinical chemistry , hematology , complete urinalysis ) within reference range test laboratory unless result deem clinically significant inclusion study investigator . A female subject childbearing potential sexually active agrees use adequate contraception screen throughout duration study . Currently take expect take thiazolidinediones within 12 week Screening . Hypersensitive thiazolidinediones . Hypertension diastolic blood pressure &gt; 100 mm Hg and/or systolic blood pressure &gt; 170 mm Hg Screening and/or Visit 2 ( Day 1 ) . Currently take angiotensin IIreceptor blocker ( ARB ) willing discontinue therapy Visit 2 ( day 1 ) remain duration study . Hypersensitive angiotensin IIreceptor blocker . Unstable angina heart failure etiology New York Heart Association functional class III IV . History myocardial infarction , cerebrovascular accident , percutaneous coronary intervention , coronary artery bypass graft transient ischemic attack within previous six month . Clinically significant cardiac conduction defect Body mass index &gt; 45 kg/m2 Screening . Moderate severe renal dysfunction Anemia Hematuria ( &gt; 1+ blood ) Screening . Triglycerides &gt; 600 mg/dL Screening . Hyperkalemia , define serum potassium level great upper limit normal , per central laboratory Screening . Alanine aminotransferase aspartate aminotransferase level great 2.5 time upper limit normal , active liver disease , jaundice Screening . History drug abuse history alcohol abuse within past 2 year . Previous history cancer , basal cell carcinoma stage 1 squamous cell carcinoma skin , remission least 5 year prior first dose study drug . Any serious disease condition would compromise subject safety , might affect life expectancy , make difficult successfully manage follow subject accord protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>angiotensin II receptor blocker</keyword>
	<keyword>thiazolidinediones</keyword>
	<keyword>combination</keyword>
	<keyword>Actos</keyword>
	<keyword>HbA1c</keyword>
	<keyword>Type 2 diabetes</keyword>
	<keyword>Drug Therapy</keyword>
	<keyword>Hypertension</keyword>
</DOC>